Advanced MedTech Announces Leadership Transition & Reports Record Revenues for FY2024
Advanced MedTech
4 min read
Advanced MedTech
WONG Yau Chung appointed Group CEO of Advanced MedTech
WONG Yau Chung appointed Group CEO of Advanced MedTech
Singapore, July 02, 2024 (GLOBE NEWSWIRE) --
Abel Ang retires as Group Chief Executive Officer after a decade and will continue to serve on the Board of Directors
Achieved record global revenues of US$335.0 million, a 15.1% increase year-over-year driven by strong performances in all segments
United States entities grew revenue by 22.3%, making up 55.4% of total revenue and 65.3% of urology revenue
Continued commitment in innovation with R&D investment increasing 20.8% year-over-year
SINGAPORE, 2 July 2024 – Advanced MedTech Holdings (AMTH or the Group), innovative global leader in urology, announced that Abel Ang will retire as Group Chief Executive Officer (CEO) as part of a planned leadership transition. Wong Yau Chung, previously Group Chief Operating Officer (COO), has assumed the role of Group CEO-designate from 1 July 2024 and will take over as Group CEO on 1 October 2024. Yau Chung will also be appointed to the Board of Directors as Group CEO, and Abel will continue to remain on the Board of Directors of AMTH.
In addition to the leadership transition, the Group also announced record revenues for the fiscal year ending 31 March 2024 (FY24). The Group achieved global revenues of US$335.0 million1, representing a 15.1% increase on a reported basis and a 17.4% rise excluding COVID-19 related revenues2. Revenues have also grown at a compound annual growth rate (CAGR) of 9.5% on a reported basis from FY22 to FY24, and at a CAGR of 16.4% from FY22 to FY24 excluding COVID-19 related revenues. This strong performance was driven by the Group's focus on its Integrated Urology Platform (IUP) strategy.
The Group’s Capital Equipment & Consumables (CEC) segment achieved revenues of US$163.6 million, a 15.0% revenue growth from the previous period and CAGR of 14.7% from FY22 to FY24 on the back of innovation-driven growth.
The Clinical Urology Services (CUS) segment achieved revenues of US$120.5 million, a 19.7% revenue growth compared to the previous period, with a CAGR of 16.7% from FY22 to FY24. Rapid expansion in the CUS segment saw more than 60,000 patient procedures performed in FY24, a 14.5% year-over-year increase and an 11.0% CAGR over the last three fiscal years.
Robotic Surgery & Tools (RST) achieved revenues of US$50.9 million, a 5.7% revenue growth from the previous period on a reported basis and a 19.8% increase excluding COVID-related revenues. Excluding COVID-related revenues, RST grew at a CAGR of 21.9% from FY22 to FY24.
This success was supported by robust growth in the United States (US) entities, where revenues grew by 22.3%. The US entities contributed 55.4% of total revenue and 65.3% of urology revenue, driven by the strong performance of new products such as Thulio, Nautilus, Axis and other urological consumables. To support future innovation-led growth, the group increased R&D investment in the year by more than 20%.
Mr. Philip Yeo, Chairman, Advanced MedTech, said, “These record results have led to AMTH being amongst the top three for investment returns within the Temasek portfolio over the last 3 years. It is a testament to the effective execution of Advanced MedTech’s vision, driven by strong leadership and a clear strategic focus. As we mark a decade under Abel’s leadership, we are appreciative of his contribution and role in shaping Advanced MedTech into one of the fastest-growing urology companies in the world – launching 30 product innovations globally. We are grateful for his dedication and are pleased to have his continued guidance on our Board of Directors.”
Mr. Wong Yau Chung, Group CEO-designate, Advanced MedTech, said, “I am honoured and excited to lead Advanced MedTech into a new chapter and its next phase of growth and innovation. I thank Abel for his guidance and partnership over the years, which have been invaluable in establishing a strong foundation for the future. With the support of our incredibly talented team, I look forward to building upon our record success in FY24 and continuing to drive growth in a sustainable manner.”
Ends
About Advanced MedTech Holdings:
Advanced MedTech Holdings is a global medical technology leader with a core focus in urology devices and contract manufacturing services. The Group serves millions of patients and physicians in 100 countries worldwide. Advanced MedTech Holdings makes strategic investments in disruptive medical technology companies, strengthening its portfolio of healthcare solutions for customers around the world. Advanced MedTech Holdings is a wholly owned subsidiary of Temasek. For more information on Advanced MedTech Holdings, please visit https://www.advanced-medtech.com/.
APPENDIX:
Wong Yau Chung – Bio:
Yau Chung is a senior executive and business leader with over 18 years of global experience in healthcare and medical devices. He joined AMTH in 2013 as Vice President, Corporate and Business Development, AMTH, before relocating to Munich and serving as Managing Director and Chief Operating Officer of AMTH’s wholly-owned subsidiary, Dornier MedTech. He was promoted to Group COO of AMTH in July 2023.
Prior to joining AMTH, Yau Chung was Deputy Director, Operations & Corporate Planning at Tan Tock Seng Hospital, and headed the Singapore Economic Development Board (EDB)’s Biomedical Division, based in their New York office. He also serves on the board of I.M.D. International Medical Devices S.p.A., headquartered in Bergamo, Italy, that specialises in medical diagnostics imaging systems.
Yau Chung holds a B.Sc. in Electrical & Computer Engineering from Cornell University on an EDB-Glaxo Scholarship and has completed the Harvard Business School’s Advanced Management Program on an AMTH Management Scholarship.
1 This information is derived from the Group's Audited Financial Statements in SGD. All financial figures have been converted to USD at respective fiscal years' average exchange rates.
2 COVID-related revenue refers to the sale of COVID test kits, ventilators and other COVID-related products in fiscal years 2021, 2022 and 2023. There were no COVID revenues from fiscal year 2024 onwards.
